- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/20 - Spiro-condensed systems
Patent holdings for IPC class C07D 471/20
Total number of patents in this class: 448
10-year publication summary
|
28
|
26
|
29
|
24
|
21
|
27
|
27
|
36
|
39
|
21
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3742 |
38 |
| Novartis AG | 10829 |
13 |
| Boehringer Ingelheim International GmbH | 4644 |
12 |
| Merck Patent GmbH | 5818 |
10 |
| Pfizer Inc. | 3380 |
9 |
| eFFECTOR Therapeutics, Inc. | 69 |
9 |
| Shionogi & Co., Ltd. | 851 |
9 |
| Vertex Pharmaceuticals Incorporated | 1595 |
8 |
| Bristol-myers Squibb Company | 4884 |
7 |
| The Regents of the University of Michigan | 4701 |
7 |
| Incyte Corporation | 1025 |
7 |
| Purdue Pharma L.P. | 500 |
7 |
| Merck Sharp & Dohme Corp. | 2190 |
6 |
| The Board of Trustees of the University of Illinois | 2695 |
6 |
| Incyte Holdings Corporation | 661 |
6 |
| SPV Therapeutics Inc. | 10 |
6 |
| Glaxosmithkline Intellectual Property Development Limited | 761 |
5 |
| Oncopia Therapeutics, Inc. | 33 |
5 |
| BeOne Medicines I GmbH | 83 |
5 |
| F. Hoffmann-La Roche AG | 7920 |
4 |
| Other owners | 269 |